Paper Details

  1. Home
  2. Paper Details

Real-Life Experience With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Turkey.

Author: BalcıUmay, Sarigul YildirimFigen, TahmazAlper, ÜserÜlkü

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study aims to analyze real-life efficacy and tolerability data of bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF) as first-line treatment for people living with HIV (PLWH). The focus is on evaluating the effectiveness and safety of this single-tablet regimen (STR) in a real-world setting.
Paper Details　
Original Abstract of the Article :
Single-tablet regimens (STRs) can increase treatment success and even improve the quality of life of human immunodeficiency virus (HIV) patients. In this study, we aim to analyze the real-life efficacy and tolerability data of people living with HIV (PLWH) initiated on or switched to bictegravir/emt...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10655161/

データ提供：米国国立医学図書館（NLM）

Bictegravir/Emtricitabine/Tenofovir Alafenamide: A New Oasis in the Desert of HIV Treatment

The battle against HIV is a continuous journey through a challenging desert landscape. Single-tablet regimens (STRs), like a convenient water source in the desert, have revolutionized HIV treatment by simplifying medication regimens and improving patients' quality of life. This study evaluates the real-life efficacy and tolerability of a new STR, bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF), in patients living with HIV.

The researchers analyzed data from patients who initiated or switched to BIC/FTC/TAF treatment, evaluating its effectiveness in suppressing the virus and its tolerability in terms of side effects. They aimed to assess the real-world performance of this new treatment option.

A Promising Oasis in the Treatment Desert

The study found that BIC/FTC/TAF was highly effective in suppressing HIV viral load, providing a much-needed oasis for patients seeking a reliable and convenient treatment option. The medication was also well-tolerated, with a low rate of side effects, further enhancing its appeal as a viable treatment strategy.

Navigating the Desert with Confidence

This research provides encouraging evidence for the effectiveness and tolerability of BIC/FTC/TAF as a first-line treatment for HIV. It offers a promising new option for individuals living with HIV, allowing them to navigate their treatment journey with greater confidence and a better quality of life.

Dr. Camel's Conclusion

This research provides a hopeful glimpse into the future of HIV treatment. The study demonstrates the effectiveness and tolerability of BIC/FTC/TAF, offering a new oasis for patients seeking a reliable and convenient treatment option. It's a testament to the ongoing efforts to find more effective and manageable solutions for those living with HIV, allowing them to navigate their treatment journey with greater ease and a brighter outlook.

Date :
  1. Date Completed n.d.
  2. Date Revised 2023-12-01
Further Info :

Pubmed ID

38022124

DOI: Digital Object Identifier

PMC10655161

Related Literature

Article Analysis
・Side Effects of emtricitabine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.